



Deltanoid Pharmaceuticals

510 Charmany Drive, Madison, WI 53719 | Phone: (608) 238-7710 | Fax: (608) 238-7715 | info@deltanoid.com

FOR IMMEDIATE RELEASE

Date: December 17, 2007

Contact: Linda Leikness or Dr. Hector Deluca

E-mail: info@deltanoid.com

Phone: (608) 238-7710

Deltanoid Pharmaceuticals Secures \$12 Million

Madison, WI — December 17, 2007 — Deltanoid Pharmaceuticals, a privately held pharmaceutical development company, announced the completion of its \$12 million (US) Series B financing, bringing total funding to date to more than \$16 million (US). Deltanoid plans to use the proceeds from this financing to advance its lead compounds and preclinical pipeline for therapies to treat patients with renal disease.

All funds were raised from previous investors in Deltanoid, led by the Wisconsin Alumni Research Foundation (WARF), an independent, non-profit technology transfer organization that supports research at the University of Wisconsin-Madison, as well as two local venture capital firms, Mason Wells, a leading Midwest private equity firm, and Venture Investors, one of the premier providers of seed and early stage venture capital in the Midwest. Other investors included a local corporation, company founders and angel investors.

Carl Gulbrandsen, managing director of WARF, has joined the Deltanoid Board of Directors. The company also announced the addition of Dr. Lori Plum, director of research and development at Deltanoid, to the Board of Directors.

“Deltanoid’s strategy has been to develop promising technologies through human trials. We currently have two drugs in phase II human trials and have garnered the attention and interest of world class pharmaceutical companies,” said Deltanoid president and CEO Hector F. DeLuca. “This financing will enable us to continue to advance our most promising preclinical lead compounds to the clinic. We will continue to consider partnership opportunities as we develop our therapies for commercialization.”

To date, Deltanoid has received income from partnerships with several pharmaceutical companies that have allowed the company to support on-going

research. The next step is to broaden that pipeline even further with this funding round.

”Deltanoid is poised to hit the mark on developing commercially superior therapies and have already realized the value of its partnerships with larger pharmaceutical companies,” said Gulbrandsen. “We look forward to Deltanoid’s continued progress in achieving the potential of these novel therapies.”

“We are impressed by how quickly Deltanoid has built a highly promising pipeline of products, and the proceeds of this round will allow them to continue to validate new compounds in the clinic,” said Managing Director Trevor D’Souza of Mason Wells. “We are committed to further investment in Deltanoid Pharmaceuticals due to its proven management team, vast scientific knowledge and its strong and committed group of investors.”

“This round was oversubscribed by just our current investors, which is a strong vote of confidence in the Deltanoid team’s ability to identify and progress commercially viable therapies. The company has an exceptionally talented team that has a track record of screening and developing early stage compounds and advancing them through the clinic. We are pleased with the tremendous progress they have made since our original investment,” commented John Neis, Managing Director of Venture Investors.

About Deltanoid

Deltanoid is a privately held drug development company involved in breakthrough treatments for osteoporosis, renal disease, psoriasis and other disease targets. Deltanoid began operations in 2001, licensing a group of technologies from the University of Wisconsin-Madison and is located in Madison, Wisconsin. To learn more about Deltanoid Pharmaceuticals, Inc. and its investors visit <http://www.deltanoid.com>.

For further information, please contact:

Linda Leikness, Chief Operations Officer ☐ 608-238-7710 / Info@deltanoid.com